This video is for instructional purposes only. The vaccine vials shown in this video may differ in appearance from actual vials of RECOMBIVAX HB.

RECOMBIVAX HB is indicated for vaccination against infection caused by all known subtypes of
hepatitis B virus.

Select safety information

• RECOMBIVAX HB is contraindicated in the presence of hypersensitivity to yeast or any component of the vaccine.
• Any serious active infection including febrile illness is reason for delaying use of the vaccine except when in the opinion of the physician, withholding the vaccine entails a greater risk.
• In 3 clinical studies involving healthy infants and children receiving 3 doses (5 mcg/0.5 mL) of RECOMBIVAX HB, the most frequent complaints (>1% of injections) included irritability, fever
  (>101°F oral equivalent), diarrhea, fatigue/weakness, diminished appetite, and rhinitis. In a study that compared the three-dose regimen (5 mcg) with the two-dose regimen (10 mcg) of the vaccine in adolescents, the overall frequency of adverse reactions was generally similar. For a list of adverse reactions, please read the Prescribing Information.
• In a group of studies involving healthy adults, the most frequent complaints (>1% of injections) in individuals receiving RECOMBIVAX HB included injection-site reactions, fatigue/weakness, headache, fever (>100°F), malaise, nausea, diarrhea, pharyngitis, and upper respiratory infection.
• As with any vaccine, vaccination with RECOMBIVAX HB may not result in seroprotection of all vaccinees.
• Before administering RECOMBIVAX HB, please read the Prescribing Information.

RECOMBIVAX HB is a registered trademark of Merck & Co., Inc.